Pfizer loses round in UK generic Lyrica battle; generics industry the broader winner
This article was originally published in SRA
Executive Summary
The judgement by a High Court judge that the launch by Actavis of a generic version of Pfizer's Lyrica (pregabalin) in the UK would not infringe a patent held by Pfizer company Warner-Lambert on one of the three uses for which Lyrica is approved1,2 has wider implications for the patenting of pharmaceuticals. Broadly speaking, the ruling is positive for generic companies.